Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Multi-center, Phase 1 Pharmacokinetic and Tolerability Study of Rilzabrutinib Given as a Single Oral Dose in Participants With Severe Renal Impairment and in Matched Participants With Normal Renal Function

NCT07853131 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT07853131
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07853131 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Multi-center, Phase 1 Pharmacokinetic and Tolerability Study of Rilzabrutinib Given as a Single Oral Dose in Participants With Severe Renal Impairment and in Matched Participants With Normal Renal Function
Lead sponsor
Sanofi
Phase
Phase 1
Overall status
Not yet recruiting
Start date
October 9, 2026
Completion date
April 21, 2027
Enrollment
16 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

healthy volunteers, renal impairment